Please provide your email address to receive an email when new articles are posted on . A review found that OCT and visual acuity were among the most popular benchmarks in the management of diabetic ...
Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch ...
At the 131st Congress of the French Society of Ophthalmology in Paris, France, the role of second-generation intravitreal anti-VEGF injections compared to corticosteroid injections in treating ...
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...
MedPage Today on MSN
IL-6 inhibitor shows promise in diabetic macular edema
Adding vamikibart to VEGF inhibition improved visual acuity and retinal anatomy ...
Please provide your email address to receive an email when new articles are posted on . The update allows for treatment beyond 6 months. Vabysmo was approved to treat macular edema following RVO in ...
Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...
People with diabetic macular edema may receive eye injections to help control their symptoms. These shots can help to improve vision and also stop the damage that causes vision issues to get worse.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results